Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Viridian Therapeutics, Inc.\DE (VRDN) Assets Average: 2014-2025

Historic Assets Average for Viridian Therapeutics, Inc.\DE (VRDN) over the last 11 years, with Sep 2025 value amounting to $579.7 million.

  • Viridian Therapeutics, Inc.\DE's Assets Average fell 14.59% to $579.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $579.7 million, marking a year-over-year decrease of 14.59%. This contributed to the annual value of $616.4 million for FY2024, which is 33.20% up from last year.
  • Viridian Therapeutics, Inc.\DE's Assets Average amounted to $579.7 million in Q3 2025, which was down 6.74% from $621.7 million recorded in Q2 2025.
  • Viridian Therapeutics, Inc.\DE's 5-year Assets Average high stood at $757.2 million for Q4 2024, and its period low was $120.5 million during Q2 2021.
  • In the last 3 years, Viridian Therapeutics, Inc.\DE's Assets Average had a median value of $579.7 million in 2025 and averaged $548.8 million.
  • As far as peak fluctuations go, Viridian Therapeutics, Inc.\DE's Assets Average spiked by 411.79% in 2021, and later decreased by 14.59% in 2025.
  • Viridian Therapeutics, Inc.\DE's Assets Average (Quarterly) stood at $212.5 million in 2021, then skyrocketed by 106.08% to $437.8 million in 2022, then decreased by 6.45% to $409.6 million in 2023, then spiked by 84.86% to $757.2 million in 2024, then declined by 14.59% to $579.7 million in 2025.
  • Its Assets Average stands at $579.7 million for Q3 2025, versus $621.7 million for Q2 2025 and $701.7 million for Q1 2025.